Kylie Gilson
About Kylie Gilson
Kylie Gilson is a Market Access Manager at Bristol Myers Squibb in Melbourne, Australia, with over 25 years of experience in various roles within the company.
Current Role at Bristol Myers Squibb
Kylie Gilson is currently the Market Access Manager at Bristol Myers Squibb in Melbourne, Australia. Her responsibilities include managing pricing matters for both new and existing brands, ensuring compliance with internal policies and PBAC requirements. Her role is crucial in facilitating the reimbursement and accessibility of critical medications in the market.
Professional Experience at Bristol Myers Squibb
Kylie Gilson has been with Bristol Myers Squibb for over 25 years, holding a series of progressive roles. She started as a Clinical Research Associate from 1998 to 2003, transitioned to Medical Affairs Manager in Virology from 2003 to 2006, and then became the Business Operations Manager for 11 months from 2006 to 2007. From 2007 to 2015, she served as the Senior Business Analyst before taking on her current role as Market Access Manager. Throughout her tenure, she has been instrumental in various capacities, contributing significantly to the company’s successes.
Educational Background and Certifications
Kylie Gilson has a robust educational background in health sciences and pharmaceuticals. She earned a Bachelor's degree in Health Science from the University of Adelaide between 1994 and 1996. She later acquired a Graduate Certificate in Drug Development from the University of NSW in 2000. Additionally, she received a Graduate Certificate in Biostatistics from the University of Melbourne from 2012 to 2014. These qualifications have equipped her with the necessary skills and expertise for her various roles in the pharmaceutical industry.
Expertise in Oncology and Virology
With over eight years of experience in developing reimbursement strategies, Kylie Gilson specializes in therapeutic areas of oncology and virology. She has made substantial contributions to the launch and market access of critical medications in these fields. She has developed multiple successful submissions to the PBAC for the reimbursement of new oncology and virology medications, ensuring that these treatments get the necessary funding and accessibility.